ABVD or BEACOPP

Autor: Christophe, Fermé, José, Thomas, Pauline, Brice, Olivier, Casasnovas, Andrej, Vranovsky, Serge, Bologna, Pieternella J, Lugtenburg, Réda, Bouabdallah, Patrice, Carde, Catherine, Sebban, Houchingue, Eghbali, Gilles, Salles, Gustaaf W, van Imhoff, Antoine, Thyss, Evert M, Noordijk, Oumédaly, Reman, Marnix L M, Lybeert, Maud, Janvier, Michele, Spina, Bruno, Audhuy, John M M, Raemaekers, Richard, Delarue, Bruno, Anglaret, Okke, de Weerdt, Zora, Marjanovic, Robbert J H A, Tersteeg, Daphne, de Jong, Josette, Brière, Michel, Henry-Amar
Rok vydání: 2017
Předmět:
Zdroj: European journal of cancer (Oxford, England : 1990). 81
ISSN: 1879-0852
0000-5584
Popis: For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and the number of cycles to be delivered remain to settle down. The H9-U trial compared three modalities of chemotherapy followed by involved-field radiotherapy (IFRT) in patients with stage I-II HL and risk factors (NCT00005584).Patients aged 15-70 years with untreated supradiaphragmatic HL with at least one risk factor (age ≥ 50, involvement of 4-5 nodal areas, mediastinum/thoracic ratio ≥ 0.35, erythrocyte sedimentation rate (ESR) ≥ 50 without B-symptoms or ESR ≥ 30 and B-symptoms) were eligible for the randomised, open label, multicentre, non-inferiority H9-U trial. The limit of non-inferiority was set at 10% for the difference between 5-year event-free survival (EFS) estimates. From October 1998 to September 2002, 808 patients were randomised to receive either the control arm 6-ABVD-IFRT (n = 276), or one of the two experimental arms: 4-ABVD-IFRT (n = 277) or 4-BEACOPPResults in the 4-ABVD-IFRT (5-year EFS, 85.9%) and the 4-BEACOPPThe trial demonstrates that 4-ABVD followed by IFRT yields high disease control in patients with early-stage HL and risk factors responding to chemotherapy. Although non-inferior in terms of efficacy, four cycles of BEACOPP
Databáze: OpenAIRE
Externí odkaz: